The short version of GHRH 类似物 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-14. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
=== Nerve supply === The muscles are innervated by thoraco-abdominal nerves, these are continuations of the T7-T11 intercostal nerves and pierce the anterior layer of the rectus sheath. Sensory supply is from the 7-12 thoracic nerves.
Microfluidics refers to a system that manipulates a small amount of fluids (10−9 to 10−18 liters) using small channels with sizes of ten to hundreds of micrometres. It is a multidisciplinary field that involves molecular analysis, molecular biology, and microelectronics. It has practical applications in the design of systems that process low volumes of fluids to achieve multiplexing, automation, and high-throughput screening. Microfluidics emerged in the beginning of the 1980s and is used in the development of inkjet printheads, DNA chips, lab-on-a-chip technology, micro-propulsion, and micro-thermal technologies. Typically microfluidic systems transport, mix, separate, or otherwise process fluids. Various applications rely on passive fluid control using capillary forces, in the form of capillary flow modifying elements, akin to flow resistors and flow accelerators. In some applications, external actuation means are additionally used for a directed transport of the media. Examples are rotary drives applying centrifugal forces for the fluid transport on the passive chips. Active microfluidics refers to the defined manipulation of the working fluid by active (micro) components such as micropumps or microvalves. Micropumps supply fluids in a continuous manner or are used for dosing. Microvalves determine the flow direction or the mode of movement of pumped liquids. Often, processes normally carried out in a lab are miniaturised on a single chip, which enhances efficiency and mobility, and reduces sample and reagent volumes.
== Research == Leptin is currently being evaluated as a potential target for the treatment of anorexia nervosa. It is hypothesized that the gradual loss of body fat mass, and more specifically the ensuing low leptin levels, escalate the preexisting drive for thinness into an obsessive-compulsive-like and addictive-like state. It was shown that short-term metreleptin treatment of patients with anorexia nervosa had rapid on-set of beneficial cognitive, emotional, and behavioral effects. Among other things, depression, drive for activity, repetitive thoughts of food, inner restlessness, and weight phobia decreased rapidly. Whether metreleptin (or another leptin analogue) is a suitable treatment for anorexia nervosa is currently unknown. Potential side effects are weight loss and the development of anti-metreleptin antibodies.
== Weathering and biodegradion of oils within the marine environment == Environmental UCMs result from highly degraded petroleum hydrocarbons and once formed they can stay largely unchanged in sediments for many years. For example, in 1969 a diesel oil spill contaminated saltmarsh sediment within Wild Harbor River, US; by 1973 only a baseline hump was observed, which remained largely unchanged within the anaerobic sediment for the next 30 years. In a study of the potential for UCM-dominated oil to be further degraded, it was concluded that even using bacteria specifically adapted for complex UCM hydrocarbons in conjunction with nutrient enrichment, biodegradation rates would still be relatively slow. Bacterial degradation of hydrocarbons is complex and will depend on environmental conditions (e.g. aerobic or anaerobic, temperature, nutrient availability, available species of bacteria etc.).
Sources: en.wikipedia.org
=== Calibration === Continuous glucose monitoring systems do not always produce readings identical to those obtained through fingerstick blood glucose testing. Differences between CGM and fingerstick values are expected due to physiological and technical factors, including the lag time between glucose levels in interstitial fluid and those in capillary blood. While the Dexcom G7 has a reported MARD of approximately 8.2%, variations of up to 20% between CGM and fingerstick readings are considered within the normal accuracy range. These differences are particularly noticeable during periods of rapid glucose change, such as after meals, physical activity, or insulin administration. As a result, CGM readings are most reliable when glucose levels are stable, and discrepancies may occur during times of fluctuation. There is an option to calibrate using a blood glucose reading taken from another device such as a blood glucose meter that uses a fingerstick lancing device, but it is not mandatory on any currently available Dexcom CGMs. The "20 rule" (or 20/20 rule) is commonly used to assess the accuracy of the CGM. If the difference between the Dexcom G6 or G7 reading and the fingerstick blood glucose meter value is within 20% (or 20 mg/dL when glucose levels are under 80 mg/dL), the sensor is operating within its expected error margin. While CGM and meter readings may not match exactly, they should generally fall within this acceptable range, especially when glucose levels are stable.
Cellular adhesion and development. The adhesion between cells is a characteristic of multicellular organisms that enables tissue specialization and therefore increases cell complexity. Adhesion of cell epithelia involves the actin cytoskeleton in each of the joined cells as well as cadherins acting as extracellular elements with the connection between the two mediated by catenins. Interfering in actin dynamics has repercussions for an organism's development, in fact actin is such a crucial element that systems of redundant genes are available. For example, if the α-actinin or gelation factor gene has been removed in Dictyostelium individuals do not show an anomalous phenotype possibly due to the fact that each of the proteins can perform the function of the other. However, the development of double mutations that lack both gene types is affected. Gene expression modulation. Actin's state of polymerization affects the pattern of gene expression. In 1997, it was discovered that cytocalasin D-mediated depolymerization in Schwann cells causes a specific pattern of expression for the genes involved in the myelinization of this type of nerve cell. F-actin has been shown to modify the transcriptome in some of the life stages of unicellular organisms, such as the fungus Candida albicans. In addition, proteins that are similar to actin play a regulatory role during spermatogenesis in mice and, in yeasts, actin-like proteins are thought to play a role in the regulation of gene expression.
==== History of opium production ==== Despite the social and cultural costs, communities in Guerrero such as La Sierra and La Montaña have continuously relied on the illegal opiate market as their primary source of income. Historical dispossession in Guerrero has weakened economic stability in under-developed regions including Atoyac de Álvarez and Ayutla de los Libres.
Lavín, José L; Kiil, Kristoffer; Resano, Ohiana; Ussery, David W; Oguiza, José A (2007). "Comparative genomic analysis of two-component regulatory proteins in Pseudomonas syringae". BMC Genomics. 8 397. doi:10.1186/1471-2164-8-397. PMC 2222644. PMID 17971244. Type strain of Pseudomonas syringae at BacDive – the Bacterial Diversity Metadatabase
== Management == Opioid use disorders typically require long-term treatment and care with the goal of reducing the person's risks and improving their long-term physical and psychological condition. First-line management involves the use of opioid replacement therapies, particularly methadone, naltrexone, morphine, hydromorphone, buprenorphine/naloxone (Suboxone), and diamorphine (heroin), which is the most effective treatment option of all drugs. Withdrawal management alone is strongly discouraged, because of its association with elevated risks of HIV and hepatitis C transmission, high rates of overdose deaths, and nearly universal relapse. This approach is seen as ineffective without plans for transition to long-term evidence-based addiction treatment, such as opioid agonist treatment. Though treatment reduces mortality rates, the first four weeks after treatment begins and the four weeks after treatment ceases are the riskiest times for drug-related deaths. These periods of increased vulnerability are significant because many of those in treatment leave programs during these periods. There is evidence that people with opioid use disorder who are dependent on pharmaceutical opioids may require a different management approach from those who take heroin.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.